Plain-English translation of NCT06599918 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a form of vitamin B3, to see if it can help slow liver scarring in people with non-alcoholic fatty liver disease who are overweight or obese. About 30 patients will receive either the medication or a placebo for 12 months, with regular check-ins to measure safety and whether the treatment helps. The study is testing whether this simple vitamin supplement might offer a new way to treat liver damage caused by fat buildup.
Fatty liver disease affects millions of overweight adults and can lead to serious scarring (fibrosis) if left untreated, but there are few proven treatments. Researchers believe this medication might help slow or stop the scarring process by reducing liver inflammation and damage.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic 5 times over 12 months. At your first visit, you'll have a physical exam, blood tests, heart tracings, and body composition scans. You'll then take either the medication or a placebo daily for a year. At follow-up visits (at 1, 3, 6, and 12 months), you'll have blood tests, vital sign checks, and repeat scans to see how your liver is responding to treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Spain